Search Within

Alexander Edward Drilon

Formats
  1. Meeting Abstract (373)
  2. Journal Article (219)
  3. Review (23)
  4. Editorial (6)
  5. Correspondence (3)
  6. Book Section (2)
  7. Research Letter (2)
  8. Book Whole (1)
  9. Guidelines (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (631)
  2. Solid Tumor Oncology Division (631)
  3. Thoracic Oncology (631)
  4. Department of Pathology and Laboratory Medicine (205)
  5. GSK Faculty (187)
  6. Human Oncology and Pathogenesis Program (156)

More Groups

People
  1. Marc Ladanyi (121)
  2. Mark Kris (89)
  3. Maria Arcila (82)
  4. David Hyman (78)
  5. Bob Li (65)
  6. Charles Rudin (64)

More People

Years
  1. 2025 (16)
  2. 2024 (61)
  3. 2023 (67)
  4. 2022 (85)
  5. 2021 (76)
  6. 2020 (81)

More Years

Publications
  1. Journal of Clinical Oncology (138)
  2. Annals of Oncology (94)
  3. Journal of Thoracic Oncology (84)
  4. Clinical Cancer Research (31)
  5. JCO Precision Oncology (24)
  6. Cancer Research (23)

More Publications

Publishers
  1. American Society of Clinical Oncology (164)
  2. Elsevier Inc. (118)
  3. Oxford University Press (113)
  4. American Association for Cancer Research (77)
  5. Nature Publishing Group (27)
  6. S. Karger AG (23)

More Publishers

Results (631)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • OncoKB: Automated somatic variant classification for rapid clinical decision making
    Meeting Abstract

    Suehnholz, S.; Nissan, M.; Zhang, H.; Kundra, R.; Lu, C.; Dhaneshwar, A.; Fernandez, N.; Cavender, K.; Preiser, B.; Konecny, J.; more...
    Journal of Molecular Diagnostics (2024)

    Fulltext@MSK | Save
  • First-in-human, phase 1 study of a selective RET inhibitor, LOXO-260, in patients with RET inhibitor refractory, RET-altered cancers
    Meeting Abstract

    Subbiah, V.; Drilon, A.; Bestvina, C.; Garon, E. B.; Wirth, L.; Worden, F.; Piha-Paul, S.; Rotow, J.; Johnson, M.; Kang, H.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Efficacy of selpercatinib by RET fusion partner in RET+ NSCLC: Results from the LIBRETTO-001 and LIBRETTO-431 trials
    Meeting Abstract

    Solomon, B.; Drilon, A.; Park, K.; Novello, S.; Nadal, E.; Besse, B.; Peled, N.; Peterson, P.; Barker, S.; Szpurka, A. M.; more...
    Asia-Pacific Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Updated tumor agnostic efficacy of selpercatinib in patients with RET fusion-positive solid tumors: LIBRETTO-001
    Meeting Abstract

    Ohe, Y.; Subbiah, V.; Sukrithan, V.; Robinson, B.; Deschler-Baier, B.; Iwasa, T.; Ohashi, K.; Goto, K.; Nishio, M.; Satouchi, M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • NVL-655 is a selective and brain-penetrant inhibitor of diverse ALK-mutant oncoproteins, including lorlatinib-resistant compound mutations
    Journal Article

    Lin, J. J.; Horan, J. C.; Tangpeerachaikul, A.; Swalduz, A.; Valdivia, A.; Johnson, M. L.; Besse, B.; Camidge, D. R.; Fujino, T.; Yoda, S.; more...
    Cancer Discovery (2024)

    Fulltext@MSK | Save
  • Precision oncology: 2024 in review
    Review

    Repetto, M.; Fernandez, N.; Drilon, A.; Chakravarty, D.
    Cancer Discovery (2024)

    Fulltext@MSK | Save
  • Lung neuroendocrine neoplasms harboring ALK, RET and other receptor tyrosine kinase fusions: Spectrum of pathologic features from conventional neuroendocrine carcinomas to unusual carcinoid-type tumors with focal mucin or adenocarcinoma components
    Meeting Abstract

    Armstrong, S.; Chang, J.; Yang, S. R.; Samuel, T.; Hussain, S.; Velez, M.; Baine, M.; Travis, W.; Drilon, A.; Quintanal-Villalonga, A.; more...
    Laboratory Investigation (2024)

    Fulltext@MSK | Save
  • Repotrectinib: Redefining the therapeutic landscape for patients with ROS1 fusion-driven non-small cell lung cancer
    Editorial

    Desilets, A.; Repetto, M.; Drilon, A.
    Clinical and Translational Medicine (2024)

    Fulltext@MSK | Save
  • Two decades of advances in clinical oncology — lessons learned and future directions
    Miscellaneous

    Banerjee, S.; Booth, C. M.; Bruera, E.; Büchler, M. W.; Drilon, A.; Fry, T. J.; Ghobrial, I. M.; Gianni, L.; Jain, R. K.; Kroemer, G.; more...
    Nature Reviews Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Reply to comment on “Brief report: Tyrosine kinase inhibitors for lung cancers that inhibit MATE-1 can lead to ‘false’ decreases in renal function”
    Correspondence

    Chen, M. F.; Wilhelm, C.; Drilon, A.; Gutgarts, V.
    Journal of Thoracic Oncology (2024)

    Fulltext@MSK | Save